• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Diabetes Drugs and Cardioprotection: A Summary for Primary Care

Slideshow

These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.


Recent study findings—many of which were presented at the recent American Diabetes Association (ADA) 81st Scientific Sessions—have demonstrated cardioprotective effects of sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). In the slides below, find concise summaries of the more significant developments in the use of diabetes drugs for ASCVD prevention.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
© 2024 MJH Life Sciences

All rights reserved.